Cesar Millan To Endorse Avivagen’s Companion Animal Health Product Vivimune Health Chews
OTTAWA, July 10, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (“Avivagen” or the “Corporation” (TSX-V:VIV) (OTC Pink:CHEXF), a life sciences innovation company with a series of patent protected products that support and optimize health, announces that the Corporation has entered into a marketing agreement with Cesar Millan, world-renowned dog behaviorist, best-selling author, and star of Nat Geo WILD’s “Dog Whisperer with Cesar Millan” and “Dog Nation.” The marketing agreement will support the promotion of Avivagen’s Vivamune Health Chews supplement for companion animals.
Avivagen’s Vivamune Health Chews supplement, taken in a once-daily chewable format, supports dogs’ skin, joints and gut health, helping to maintain healthy hip and joint function, promoting normal mobility, and supporting dogs with occasional stiffness. It also promotes healthy skin and soothes skin-related issues associated with seasonal allergies.
After meeting with Cesar Millan, Kym Anthony, Chairman of the Board and Interim CEO of Avivagen said, “We’re thrilled that Cesar has decided to endorse our product because he genuinely cares about the health and welfare of dogs. This endorsement will play an integral role in the relaunch of Vivamune, Avivagen’s companion animal product in the U.S. – another opportunity for Avivagen that now includes OxC-beta™ for Livestock and Vivamune for companion animals.”
“My focus has always been on products that really work for dogs,” Millan commented. “I have a team of veterinarians and doctors that I work with to help evaluate products. Everyone was impressed with Vivamune Health Chews. It’s shown remarkable results with our pack already and I’m excited to help this innovative Canadian company share their product with more people.”
Millan further commented “It’s unlike anything we’ve seen available for dogs before: a nature-inspired, scientifically-proven solution that helps to promote health from within the dog’s own immune system. It makes sense: start by ensuring a healthy immune system and end up with a healthier dog overall. In the training world we know: it’s all about supporting a healthy foundation.”
Tracy Gillett, Marketing Manager for Avivagen, said: “Securing the opportunity to work with Cesar and his team is a reflection of the confidence we have in our product. Having worked as a veterinarian in Australia and the UK for many years, I would have loved to have had access to a supplement like Vivamune. Skin issues and joint problems have a negative effect on the quality of life of pets so I’m very excited that we’ll be able to help more dogs as a result of this agreement.”
Vivamune is only available for sale in the US. Visit www.vivamunehealth.com for more information.
About Cesar Millan
New York Times best-selling author and twice Emmy-nominated television personality Cesar Millan has earned a trusted reputation as the preeminent authority in the field of dog rehabilitation. With more than 25 years of experience working with canines, Millan uses a philosophy of trust, respect and love to rehabilitate aggressive, frightened and neurotic dogs while educating owners on how their own behavior affects their pets. Millan extends his reputation in dog training and care through retail and home entertainment products, books and Cesarsway.com, which have become top resources for dog help and advice; through the ongoing work of the Cesar Millan Pack Project; and through connecting with TV audiences via his television series, Cesar Millan’s Dog Nation. For more information, visit www.cesarsway.com. Follow Cesar on Facebook (cesar.millan), Twitter (@cesarmillan) and YouTube (CesarMillan).
See:
https://www.facebook.com/cesar.millan/
https://twitter.com/cesarmillan (@cesarmillan)
https://www.instagram.com/cesarsway/
https://www.youtube.com/user/CesarMillan
https://www.cesarsway.com/
The contents of these social media and websites are expressly not incorporated by reference by Avivagen.
About Avivagen
Avivagen Inc. is a life sciences corporation that has developed a scientifically-proven product for replacing antibiotics in livestock feeds and to otherwise benefit human and animal health. Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.
About Vivamune
Vivamune is an all-in-one chew that can dramatically simplify your pet’s supplement routine. Featuring a new and revolutionary immune supporting active ingredient: OxC-beta™, Vivamune targets joints, skin and digestive health all in a single, tasty chew your pet will love. Vivamune is available for sale today in the US. For more information, visit www.vivamunehealth.com.
See:
https://www.facebook.com/vivamune
https://twitter.com/vivamune
https://www.youtube.com/channel/UCmxZnuvZcmdlbiW_zeTK61A
https://www.pinterest.com/vivamune/
http://www.vivamunehealth.com/contact-us/
About OxC-beta™ Technology
OxC-beta™ is Avivagen’s proprietary formulation of fully oxidized ß-carotene derivatives that has shown some very promising benefits for humans and animals alike. According to peer-reviewed, clinical and laboratory studies, OxC-beta™ has been shown to have the unique ability to prime an organism’s innate immune system.
OxC-beta™ Livestock
OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. The Company intends to accelerate market access and the commercial uptake of its OxC-beta™ Livestock product, an innovative product that has the potential to eliminate the use of antibiotics as growth promoters in livestock feed, a problem that needs an urgent solution and which represents a multi-billion dollar market.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, the following: whether Avivagen's relaunch of its Vivimune product will be successful, whether Vivimune can deliver the benefits described in this press release to any or all dogs, if at all, whether Vivimune can promote or support dogs’ skin, joints and gut health, normal mobility, or support dogs with occasional stiffness, or maintain healthy hip and joint function, relieve stiffness, promote healthy skin and soothe skin-related issues associated with seasonal allergies in any or all dogs, if at all, Avivagen’s ability to continue as a going concern, if Avivagen can commercialize products to replace the antibiotics used in livestock feeds, if it can accelerate market access and the commercial uptake of its OxC-beta™ Livestock product and its Vivimune Health Chews supplement, whether OxC-beta™ will continue to show promising benefits for humans and animals alike; whether Avivagen can continue to protect its intellectual property; if Avivagen’s innovative products have the potential to eliminate the use of antibiotics as growth promoters in livestock feed.
Readers should also refer to the risk factors in Avivagen’s Annual Information Form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2017 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
For more information: Avivagen Inc. Drew Basek, Director of Investor Relations 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733 E-mail: d.basek@avivagen.com Kym Anthony, Interim Chief Executive Officer 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164 Website: www.avivagen.com